Approved indications: In the United States, Tabrecta is FDA-approved for adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to MET exon 14 skipping, confirmed by an FDA-approved test.

Off-label uses: Outside this approved setting, capmatinib may occasionally be considered for other MET-driven cancers (such as MET-amplified NSCLC or other solid tumors) mainly in clinical trials or when standard options are exhausted, but evidence for these uses is early-phase and more limited, so benefit is less certain.

Efficacy expectations:

• In the main GEOMETRY mono-1 study, about two-thirds of previously untreated patients and around half of previously treated patients had meaningful tumor shrinkage, with many responses lasting close to a year or longer.
• Improvements on scans and in symptoms often appear within the first few months, though some patients have slower or no visible response.
• Not all patients benefit, and while responses can be durable, most cancers eventually progress and ongoing imaging is needed to track effect.

Comparison to similar drugs: Tabrecta is one of two MET inhibitors (along with tepotinib) approved for MET exon 14–altered metastatic NSCLC; their response rates and durability are broadly similar in separate studies, and no direct head‑to‑head trials have shown one to be clearly superior.

Typical dosing and how to take it: For adults, the recommended dose is 400 mg of Tabrecta taken by mouth twice daily (morning and evening), with or without food. Tablets should be swallowed whole with water and not broken, crushed, or chewed, and doses are usually continued as long as they are working and side effects are manageable.

Dose adjustments and special instructions: If troublesome side effects occur, the dose may be reduced stepwise (for example to 300 mg twice daily, then 200 mg twice daily) or the medicine temporarily stopped; people with severe liver or kidney problems may need individualized dosing and closer follow-up. Take doses at about the same times each day, and follow instructions about blood tests and scans to monitor safety and effectiveness.

Missed doses and overdose: If a dose is missed or vomited, do not take an extra dose to make it up; simply take the next scheduled dose at the usual time. In case of taking more tablets than prescribed, contact a poison control center (1-800-222-1222 in the U.S.) or seek emergency medical care immediately, bringing the medication bottle if possible.

Common side effects:

• Very common effects (in more than 1 in 5 patients) include swelling of the hands, feet, or other areas (edema), nausea, vomiting, fatigue or weakness, muscle or bone pain, shortness of breath, cough, and decreased appetite.
• These usually begin in the first weeks to months of treatment and are often mild to moderate but can occasionally be more severe and require dose interruption or reduction.

Serious or rare adverse effects needing urgent care:

• Lung inflammation (interstitial lung disease/pneumonitis) causing new or worsening cough, fever, or trouble breathing.
• Liver injury signaled by yellowing of skin or eyes, dark urine, right‑sided abdominal pain, or severe fatigue.
• Pancreas problems with severe upper abdominal pain (often radiating to the back), nausea, vomiting, or unexplained weight loss.
• Serious allergic reactions with fever, chills, rash, itching, dizziness, or swelling.

Warnings and precautions: Tabrecta can harm an unborn baby, so effective contraception is recommended for females and males with partners of reproductive potential during treatment and for 1 week after the last dose; breastfeeding is not recommended during treatment and for 1 week after the last dose. It is not known to be safe or effective in children. People with significant liver or kidney disease, preexisting lung disease, or a history of pancreatitis need careful assessment and closer monitoring. Because Tabrecta can increase sensitivity to sunlight, patients should limit sun exposure and use protective clothing and sunscreen.

Safety compared with other treatments: Compared with traditional chemotherapy, Tabrecta tends to cause less hair loss and blood count suppression but more peripheral swelling, liver and pancreatic lab changes, and photosensitivity; severe lung, liver, or pancreas toxicities are uncommon but clinically important.

Side-effect reporting and safety updates: Side effects can be reported to the FDA MedWatch program (online or at 1-800-FDA-1088) and to Novartis at 1-888-669-6682, and updated safety information is available through the FDA and manufacturer websites.

Drug and supplement interactions: Strong or moderate CYP3A enzyme inducers (such as rifampin, carbamazepine, phenytoin, or St. John’s wort) can lower Tabrecta levels and should generally be avoided. Strong CYP3A inhibitors (such as certain antifungals or some HIV medicines) can raise Tabrecta levels and increase side effects, so closer monitoring may be needed. Tabrecta itself can raise blood levels of some other medicines that are processed by CYP1A2, P‑gp, BCRP, or MATE transporters (for example theophylline, tizanidine, digoxin, some statins, or metformin), so dose adjustments or careful monitoring of those drugs may be required.

Food, alcohol, and other products: Tabrecta can be taken with or without food, and no specific food is prohibited, but heavy alcohol use may increase the risk of liver problems and should be discussed with the care team. Because of photosensitivity risk, patients should minimize direct sunlight and avoid tanning beds, using sunscreen and protective clothing during treatment.

Precautions and conditions needing extra care: Before starting Tabrecta, patients should tell their clinician about all medical conditions, especially lung disease, liver or kidney problems, history of pancreatitis, or prior serious drug allergies, and provide a full list of prescription and over‑the‑counter medicines, vitamins, and herbal supplements. Tabrecta is not recommended during pregnancy or breastfeeding, and effective birth control is needed during therapy and for 1 week after the last dose.

Monitoring needs: Routine monitoring typically includes liver function tests, pancreatic enzymes (amylase and lipase), blood counts and chemistries, and regular imaging to assess tumor response. Patients should also be monitored for new or worsening respiratory symptoms, signs of liver or pancreas injury, swelling, or allergic reactions throughout treatment.

Q: Who is Tabrecta for, and how is it different from regular chemotherapy?
A: Tabrecta is for adults with metastatic non-small cell lung cancer whose tumors have a MET exon 14 skipping mutation; unlike standard chemotherapy, it is a targeted pill that blocks a specific cancer-driving protein, often with a different side-effect profile.

Q: How long will I need to stay on Tabrecta?
A: Treatment is usually continued as long as the cancer is controlled and side effects remain manageable, so many patients stay on it for months or longer, with periodic scans to reassess.

Q: What should I do if I miss a dose or vomit after taking Tabrecta?
A: If you miss a dose or vomit after taking it, do not take an extra dose; simply wait and take your next dose at the regular scheduled time.

Q: Can I go out in the sun while taking Tabrecta?
A: You can be outdoors, but because Tabrecta may increase sensitivity to sunlight, you should limit direct sun exposure, wear protective clothing, and use a broad-spectrum sunscreen.

Q: Can I drink alcohol during treatment with Tabrecta?
A: Occasional light drinking may be acceptable for some people, but because both alcohol and Tabrecta can affect the liver, you should discuss your alcohol use with your oncology team before drinking.

Q: Is Tabrecta safe in pregnancy or while breastfeeding?
A: Tabrecta can harm an unborn baby and is not recommended during pregnancy or while breastfeeding, so effective birth control is needed during treatment and for 1 week after the last dose, and breastfeeding should be avoided during this time.

Storage: Store Tabrecta tablets at room temperature (68°F to 77°F / 20°C to 25°C), in the original bottle with the desiccant cartridge, protected from moisture, and keep the container tightly closed and out of reach of children and pets; discard any tablets remaining more than 6 weeks after first opening the bottle.

Disposal: When treatment is stopped or tablets expire, use a medicine take-back program if available; if not, mix unused tablets (kept whole) with an undesirable substance in a sealed container before placing in household trash, and do not flush tablets down the toilet unless specifically instructed.